`Sent:
`To:
`Subject:
`
`kate dawson/cambridge/biogenidec;nsf;kate.dawson@biogenidec.com;smtp
`Tue Nov 21 2006 16:01:32 EST
`
`Re: BG00012 Phase 3 Clinical Trials
`
`Dear Professor
`
`
`
`Thank you for your reply and acceptance of this offer. As it is already quite late in Poland, I will
`try to contact you tomorrow.
`
`I am looking forward to speaking with you and I am glad you will be a member of this
`committee.
`
`Thank you
`
`Kate
`
`Kate Dawson M.D.
`Associate Director
`Clinical Development, Neurology
`biogen idec
`office 617 914-6377
`fax 617 679-3518
`
`NOTE All information contained in this communication is CONFIDENTIAL.
`
`
`
`21-Nov-2006 02:23 PM
`
`Please respond to
`
`Message Size: 4.5 KB
`
`
`
`To
`Kate Dawson <kate.dawson@biogenidec.com>
`cc
`
`Subject
`Re: BG00012 Phase 3 Clinical Trials
`
`Page 1 of 3
`
`Biogen Exhibit 2210
`Coalition v. Biogen
`IPR2015-01993
`
`
`
`Dear Dr. Dawson.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Thank you for inviting me to the advisory connnirtee for the 109 MS 301
`
`
`
`
`
`
`
`
`
`
`
`
`study. I would be pleased to work with you and Biogen. My contact
`
`
`
`telephone numbers are:
`
`
`
`
`
`
`
`
`Looking forward to healing from you.
`
`
`
`
`
`
`Kate Dawson napisal(a):
`">
`
`
`
`>ne=»-nnj
`>
`
`
`> >
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`I am a neurologist and the Biogen Idec Medical Director for the BGI 2
`
`
`
`
`
`
`
`
`
`
`
`
`‘> Phase 3 Clinical Trials. I am writing because Iwould like to speak
`
`
`
`
`
`
`
`
`
`
`
`> with you about paiticipating on the advisory committee for 109 MS 301,
`
`
`
`
`
`
`
`
`
`
`
`
`> the placebo-controlled, 2-year study of two doses of BG12 for patients
`> with RRMS.
`
`‘>
`
`
`
`
`
`
`
`
`
`
`
`> You have been highly 1'econJn1ended for this position by Prof.‘
`
`
`
`
`
`Page 2 of 3
`
`
`
`> who is the Coordinating/Lead Principle Investigator for this trial,
`> and Prof.
` who will also be an advisory committee
`> member. Biogen Idec is always looking to work with leaders in the MS
`> field, and I would welcome the opportunity to discuss the clinical
`> trial design with you, and answer any questions you might have.
`>
`> Therefore, I was hoping you could provide me with a way and a
`> suggested time to contact you, or alternately you can contact me at
`> the numbers listed below (My time zone is six hours behind yours).
`>
`> Thanks in advance for your time and consideration of this matter, and
`> I hope that this program can benefit from your participation.
`>
`>
`> Best Regards,
`>
`>
`> Kate Dawson M.D.
`> Associate Director
`> Clinical Development, Neurology
`> biogen idec
`> office 617 914-6377
`> fax 617 679-3518
`>
`> NOTE All information contained in this communication is CONFIDENTIAL.
`>
`
`Page 3 of 3
`
`